Functional Platinum Response Assays In Lung Cancer | 16408
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Functional platinum response assays in lung cancer

3rd International Conference and Exhibition on Pathology

Christof Granzow

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.012

In a recent, blinded clinical study on advanced lung cancer (stages IIIb and higher), the prognostic potential of an innovative, cell-based ex vivo-assay was investigated with respect to the efficacy of platinum (Pt)-based chemotherapy. High Pt sensitivity ex vivo was always associated with partial tumor remission. The onset of Pt resistance of the tumors was depicted quantitatively in the tumor explants. Chemotherapy outcomes at various levels of Pt resistance in the explants correlated plausibly with the additional cytostatic drugs used in combination with Pt, particularly pemetrexed. Ex vivo-assays for cellular Pt response performed under conditions preventing photochemical artifacts should contribute to future optimizing of Pt- based lung cancer chemotherapy.
Christof Granzow, M.D., is a Professor Emeritus of Biochemistry, University of Heidelberg, Germany. His group showed that the poor reproducibility of chemoresponse assays due to riboflavin-mediated photochemical cell culture artifacts. At FLACOD GmbH, Heidelberg, he is concerned with novel protocols to predict chemotherapy outcomes.